Due to the nature of Pharma/Biotech R&D, it is a costly, time-consuming affair, notwithstanding the ever-growing competition and fluctuating environments. Developing drug portfolios demands PPM to be highly innovative, structured and well organised.
Vonlanthen Group of Companies shall be hosting an event to overcome these challenges, through an expert panel of speakers and delegates to discuss, innovate and resolve critical issues for fast track solutions to complex PPM problems.
Key Practical Learning Points of the Summit:
Who Should Attend:
Chief Executives, Directors, Vice Presidents, Department Heads, Leaders and Managers specialising in:
Christoph Kalis Associate Director PMO Novartis
Dr. Simon Preston Global Regulatory Affairs, Patient Safety and Quality Assurance AstraZeneca
Dr. Dorothee Breuer-Giersiepen Director Clinical Project Management, Real-World Evidence Solutions QuintilesIMS
Sigrún Stefánsdóttir Director Strategic Launch Management & PMO Actavis - a Teva company
Alexis Poulet Global Head of R&D Finance & Controlling Ferring Pharmaceuticals
Kamil Mroz Managing Director CENPREX Sprl
David Carrasco Strategic Operations Director, Real-World Evidence Solutions QuintilesIMS
Dr. Kenny Blades Director, Global Program Management DOCS / ICON ICON PLC
Please, complete details below:
Please, complete details below and you will get Agenda via E-mail:
Please, complete details below and you will get 500 € Document Package: